The mechanism of GLP-1 agonism explained: insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite signaling.
Week-by-week timeline of weight loss, side effects, and titration on semaglutide and tirzepatide.
Eli Lilly's Foundayo (orforglipron) was FDA-approved April 2026. Mechanism, dosing, efficacy, and how it stacks up against injectables.
Patients describe quieted food noise as the most surprising effect of GLP-1. Here's the neuroscience and what to expect.
The standard titration ladders for semaglutide and tirzepatide, plus when to slow down or pause.
Sub-therapeutic GLP-1 dosing for tolerability and longevity goals — current evidence and risks.
Tapering vs steady-state vs intermittent dosing for weight maintenance on GLP-1.
Weight regain after stopping GLP-1 is common — but it's not inevitable. Here's the data and the off-ramping protocol.
Protein targets, fiber, hydration, and meal timing on semaglutide or tirzepatide.
Resistance training is non-negotiable on GLP-1. Here's the actual protocol that preserves lean mass.
Up to 40% of weight lost on GLP-1 can be lean mass without intervention. Here's how to keep that number low.
Why 1.6 g/kg body weight is the recommended protein floor on GLP-1 — and how to actually hit it when appetite is suppressed.
Sleep changes, vivid dreams, and apnea improvement on GLP-1 therapy.
Constipation, nausea, and fatigue on GLP-1 are often hydration problems. Targets and tactics.
Site rotation, needle length, prep technique, and disposal — the clean version.
Refrigeration rules, room-temperature stability windows, and travel handling.
How to fly with GLP-1, international rules, and cold-chain logistics for long trips.
Standard guidance on missed semaglutide and tirzepatide doses.
GLP-1 is contraindicated in pregnancy. Here's the washout guidance and what's known about post-discontinuation conception.
How insurance coverage, dosing, and prior auth differ between Type 2 diabetes and chronic weight management.
The oral GLP-1 pipeline — from Rybelsus to Foundayo to retatrutide oral candidates.